Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) Versus Chemotherapy Alone in Patients With Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

NCT00047736 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00047736
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00047736 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Randomized, Double Blind, Multicenter Trial of Tarceva (Erlotinib) Plus Chemotherapy (Carboplatin and Paclitaxel) Versus Chemotherapy Alone in Patients With Advanced (Stage IIIb or IV) Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Lead sponsor
Genentech, Inc.
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2001
Completion date
July 31, 2003
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer